Identity
- Trade Name
- BIOCLONE FDA UDI
- Generic Name
- Anti-B red blood cell grouping IVD, antibody FDA UDI
- Device Name
- ANTI-B (MURINE MONOCLONAL BLEND) BIOCLONE 15X10ML FDA UDI
- Model / Reference
- 711320 FDA UDI
- Description
- ANTI-B (MURINE MONOCLONAL BLEND) BIOCLONE 15X10ML FDA UDI
Identifiers
- Catalog Number
- 711320 FDA UDI
- Primary DI / UDI-DI
- 10758750003075 FDA UDI
- GMDN Term
- Anti-B red blood cell grouping IVD, antibody FDA UDI
Classification
- Commercial Distribution
- In Commercial Distribution FDA UDI
Clinical & Handling
Sterile
No
FDA UDI
Single Use
No
FDA UDI
Implantable
No
FDA UDI
Contains Latex
Yes
FDA UDI
Prescription Use
Yes
FDA UDI
Over-the-Counter
No
FDA UDI
Convenience Kit
Yes
FDA UDI
Combination Product
No
FDA UDI
HCT/P
No
FDA UDI
Premarket Exempt
No
FDA UDI
Lot / Batch Number
Yes
FDA UDI
Serial Number
No
FDA UDI
Expiration Date
Yes
FDA UDI
Manufacturing Date
No
FDA UDI
Category: Anti-B red blood cell grouping IVD, antibody
Bioclone by Ortho-Clinical Diagnostics — FDA UDI — listed in FDA GUDID — regulatory data on deviCERTS
Similar devices
Also classified as Anti-B red blood cell grouping IVD, antibody.
- Anti-B (Murine Monoclonal) Series 3 — IMMUCOR, INC.
- Seraclone® Anti-B (ABO2) — Bio-Rad Medical Diagnostics GmbH
- Anti-B (Murine Monoclonal) Gamma-clone — IMMUCOR, INC.
- Beckman Coulter® PK® Systems Anti-B (164B5G10+7821D9) — DIAGAST
- Beckman Coulter® PK® Systems Anti-B (9621A8) — DIAGAST
- Anti-B (Murine Monoclonal) Series 3 — IMMUCOR, INC.
- Anti-B (AB02) — DIAGAST
- MTS — MICRO TYPING SYSTEMS, INC
Authorization Coverage (1 country)
Regulatory Authorizations
United States Pending data
FDA UDI
| Source | Region | Type | Cert / Approval No. | Class | Status |
|---|---|---|---|---|---|
| FDA UDI | United States | FDA UDI | Registered in GUDID | N/A | Pending data |
Is this your device? Claim it to add documentation and request validation.
Manufacturer
- Manufacturer
- Ortho-Clinical Diagnostics
Sources (1)
- FDA UDI 901907fe-5204-4dc7-9611-82bc2593f8af 35 fields · synced Jun 8, 2026